What the Prevnar 13 TV commercial - Prevention is about.
Prevnar 13 is a vaccine developed by Pfizer to provide protection against 13 strains of pneumococcal bacteria. The vaccine is recommended for children and adults who are at higher risk of pneumococcal infections, such as older adults, individuals with weakened immune systems, and individuals with certain medical conditions.
In the Prevnar 13 TV Spot, 'Prevention', the emphasis is on the importance of prevention in healthcare. The ad shows a series of everyday activities, such as riding bikes, playing in the pool, and spending time with family, but with a twist. Each activity is shown in reverse, as if rewinding time, to show how everything can be undone in the blink of an eye if someone gets sick.
The ad then emphasizes that "Prevention is Everything" and promotes Prevnar 13 as a key part of preventative care. The spot shows a diverse range of adults getting the Prevnar 13 vaccine and encourages viewers to talk to their healthcare provider about whether the vaccine is right for them.
Overall, the Prevnar 13 TV Spot, 'Prevention' effectively conveys the importance of taking preventative measures to protect one's health, including through vaccination. The ad's use of everyday activities in reverse creates a sense of urgency and highlights how quickly one's life can be impacted if they don't take steps to prevent illness.
Prevnar 13 TV commercial - Prevention produced for
Prevnar 13
was first shown on television on August 29, 2018.
Frequently Asked Questions about prevnar 13 tv spot, 'prevention'
This vaccine is used to help protect from infection due to a certain bacteria (Streptococcus pneumoniae). This bacteria can cause ear infection or other more serious infections (such as pneumonia, meningitis). Some brands are approved for use only in children, while others can be used in both children and adults.
Prevenar 13 is used to protect children aged between six weeks and 17 years against invasive disease, pneumonia (infection of the lungs) and acute otitis media (infection of the middle ear) caused by S. pneumoniae. It is also used to protect adults and the elderly against invasive disease and pneumonia caused by S.
Development timeline for Prevnar 13
| Date | Article |
|---|
| Feb 24, 2010 | Approval FDA Approves Prevnar 13 Pneumococcal Disease Vaccine |
| Jan 5, 2010 | Pfizer Provides U.S. Regulatory Update On Prevnar 13 Vaccine |
| Aug 12, 2009 | Wyeth Provides Regulatory Update on Prevnar 13 in the United States |
PCV13 in Adults
It demonstrated: 46% efficacy against vaccine-type pneumococcal pneumonia. 45% efficacy against vaccine-type non-bacteremic pneumococcal pneumonia. 75% efficacy against vaccine-type IPD.
– Administer 1 dose of PCV13 at least 1 year after the most recent pneumococcal vaccine dose. – Administer a second dose of PPSV23 at least 8 weeks after PCV13 and at least 5 years after the previous dose of PPSV23 (note: a second dose is not indicated for those with CSF leaks or cochlear implants).
Prevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12-15 months of age. a Dose 1 may be given as early as 6 weeks of age. b The recommended dosing interval is 4 to 8 weeks. c The fourth dose should be administered at approximately 12-15 months of age, and at least 2 months after the third dose.
One dose of PCV13 is recommended for adults: 65 years or older who have not previously received PCV13. 19 years or older with certain medical conditions and who have not previously received PCV13.
PCV13 Added Protection Against More Serotypes Compared with PCV7. In 2010, FDA licensed PCV13 for children. This vaccine provided protection against infections caused by 6 more serotypes than PCV7. PCV13 caused the body's immune system to create antibodies, which help fight pneumococcal bacteria, similar to PCV7.
(NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 ...
Depending on which shots you received and when you got them, it may be a good idea to receive a booster after five years. Your doctor can help you determine if you need additional vaccines. If PCV20 (Prevnar 20) is available, it's the only shot you'll need.
Prevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12-15 months of age. a Dose 1 may be given as early as 6 weeks of age. b The recommended dosing interval is 4 to 8 weeks. c The fourth dose should be administered at approximately 12-15 months of age, and at least 2 months after the third dose.
Received PCV13 at Any Age and PPSV3 Before Age 65 Years
Give 1 dose of PCV20 or PPSV23. Regardless of vaccine used, their series is complete. The PCV20 dose should be given at least 5 years after the last pneumococcal vaccine. The PPSV23 dose should be given at least 5 years after the last PPSV23 dose.
